JPMorgan Chase & Co. Acquires 2,062,563 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

JPMorgan Chase & Co. lifted its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 475.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,495,922 shares of the company's stock after acquiring an additional 2,062,563 shares during the quarter. JPMorgan Chase & Co. owned about 2.76% of Caribou Biosciences worth $3,969,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. US Bancorp DE lifted its position in shares of Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after purchasing an additional 26,467 shares during the last quarter. Thrive Wealth Management LLC acquired a new position in Caribou Biosciences during the 4th quarter valued at $51,000. Intech Investment Management LLC boosted its holdings in Caribou Biosciences by 69.4% in the 4th quarter. Intech Investment Management LLC now owns 37,478 shares of the company's stock valued at $60,000 after purchasing an additional 15,352 shares during the period. Sei Investments Co. acquired a new position in shares of Caribou Biosciences during the fourth quarter valued at about $102,000. Finally, Barclays PLC lifted its stake in shares of Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company's stock valued at $255,000 after buying an additional 71,463 shares during the period. Institutional investors and hedge funds own 77.51% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CRBU shares. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Wednesday, March 19th. Bank of America lowered their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences presently has a consensus rating of "Buy" and an average price target of $10.33.

Caribou Biosciences Stock Performance

Shares of NASDAQ CRBU traded down $0.09 during mid-day trading on Friday, hitting $0.78. 529,551 shares of the stock were exchanged, compared to its average volume of 1,555,310. Caribou Biosciences, Inc. has a twelve month low of $0.66 and a twelve month high of $3.93. The stock's fifty day simple moving average is $0.99 and its two-hundred day simple moving average is $1.54. The company has a market cap of $72.54 million, a P/E ratio of -0.47 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. As a group, equities research analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.